Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report

We report the successful use of anti-CD20 therapy in a child with refractory myasthenia gravis (MG), an antibody-mediated autoimmune disease, who did not respond to conventional therapy. After initiation of anti-CD20 therapy, clinical improvement (muscular strength, pulmonary function) was observed.

Saved in:
Bibliographic Details
Published in:The Journal of pediatrics 2003-11, Vol.143 (5), p.674-677
Main Authors: Wylam, Mark E, Anderson, Peter M, Kuntz, Nancy L, Rodriguez, Vilmarie
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents - therapeutic use
Child
Female
Humans
Myasthenia Gravis - drug therapy
Rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the successful use of anti-CD20 therapy in a child with refractory myasthenia gravis (MG), an antibody-mediated autoimmune disease, who did not respond to conventional therapy. After initiation of anti-CD20 therapy, clinical improvement (muscular strength, pulmonary function) was observed.
ISSN:0022-3476
1097-6833
DOI:10.1067/S0022-3476(03)00300-7